Research group and committee session
| Diabetes together with NAFLD : Translational understanding for NAFLD in T2DM |
16:00~17:30 / Thursday 11 October Convention Hall B 4F Chairman: Chul-Hee Kim, Dae Ho Lee |
Overview |
|---|---|---|
Organizer: KDA research group on fatty liver disease This session entitled with 'diabetes together with NAFLD' is translational session and designed to provide a place for clinicians and basic researchers to understand the novel pathophysiologies and potential therapeutic areas for NAFLD in patient with diabetes. In this session, a variety of therapeutic targets based on the novel NAFLD pathophysiologies especially in T2DM patients, including autophagy, inflammasone, FXR/PPARa, organokines and important immunologic regulators, will be presented and discussed. This session will be the first step toward better understanding the importance of NAFLD in T2DM. |
||
|
RG1-1 Growth differentiation factor 15: an important immunometabolic regulator in hepatic inflammation and insulin resistance | |
|
RG1-2 New therapeutic approaches for non-alcoholic steatohepatitis: autophagy and inflammasome | |
|
RG1-3 Nutrient sensing nuclear receptors control liver energy balance | |
|
RG1-4 Organokines and non-alcoholic fatty liver disease (NAFLD) | |
| Clinical trials in Korea: Noteworthy clinical trials in Korean type 2 diabetes |
09:00~10:40 / Friday 12 October Flamingo Chairman: Hyuk-Sang Kwon, Moon-Suk Nam |
Overview |
|---|---|---|
Organizer: Committee of Clinical Practice Guideline This session entitled with 'clinical trials in Korea' is clinical session and designed to provide a place for clinicians to understand the noteworthy clinical trials in Korean patients with type 2 diabetes. In this session, results of clinical trials of Korean patients with type 2 diabetes, including degludec, liraglutide, dapagliflozin, evogliptin, and teneligliptin, will be presented and discussed. By understanding the results of clinical studies conducted in Koreans, we will help to understand the characteristics and treatment directions of diabetes in Koreans. |
||
|
RG2-1 Efficacy and safety of lixisenatide in Korean type 2 diabetic patients with basal insulin failure | |
|
RG2-2 Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Korean patients with type 2 diabetes | |
|
RG2-3 Liraglutide provides similar glycaemic control as glimepiride and reduces body weight and hypoglycaemia events in Asian population with type 2 diabetes: the Korean subgroup analysis | |
|
RG2-4 Efficacy and safety of dapagliflozin in Korean patients with type 2 diabetes | |
|
RG2-5 Teneligliptin clinical trial in Korea | |
|
RG2-6 Efficacy and safety of evogliptin in Korean patients with type 2 diabetes | |
|
RG2-7 Summary | |
| Diabetes in Asia : Sharing real experience of diabetes epidemiologic research |
16:20~18:00 / Friday 12 October Convention hall C Chairman: Takashi Kadowaki, Doo-Man Kim |
Overview |
|---|---|---|
Organizer: Committee of International Liaison This session entitled with 'Diabetes in Asia' is a clinical session and designed to make an international occasion for gathering of Asian experts (clinicians and epidemiologic researchers) in diabetes care. The representatives participating speakers and panels from more than 10 countries from all over the Asia will present and discuss their experience in diabetes prevention, perspectives and their healthcare system. The ultimate goal of this session resides in continuous collaboration and friendship among the Asian countries and diabetes societies in the prevention and management of diabetes in Asia in the future. |
||
|
RG3-1
Effect of an intensified multifactorial intervention on cardiovascular and renal outcomes and mortality in type 2 diabetes (J-DOIT3)
|
|
|
RG3-2
Developmental origins of T2DM: a perspective from China
|
|
|
RG3-3 Diabetes epidemic and diabetes care system in Korea | |
|
|
Touch Khun (Preah Kossamak Hospital, Cambodia) Altaisaikhan Khasag (Mongolian National University, Mongolia) Ikram Shah Ismail (University of Malaya, Malaysia) Wannee Nitiyanant (Mahidol University, Thailand) Alimov Anvar Valievich (Ministry of Health, Uzbekistan) |
|
| Diabetes guideline : Diabetes guidelines in perspectives of Asian diabetes phenotype |
09:00~11:00 / Saturday 13 October Emerald Hall B Chairman: Hyun Shik Son, Young Sik Choi |
Overview |
|---|---|---|
Organizer: Committee of Clinical Practice Guideline This session entitled with 'diabetes guidelines' is clinical session and designed to provide a place for clinicians to understand the cardiovascular risk factor targets in Asian patient with diabetes. In this session, optimal blood pressure goals, LDL cholesterol management (moderate vs. high intensity statin) and glycemic control goals (HbA1c <6.5% vs. <7%) in Asian diabetes will be presented and discussed. This session will provide updated cardiovascular risk factor targets in diabetes. |
||
|
RG4-1 Optimal BP control target in Asian diabetes; the lower, the better? | |
|
RG4-2
LDL-C management in Asian diabetes; moderate vs. high intensity statin - a lesson from EMPATHY study
|
|
|
RG4-3 Glycemic control target in Asian diabetes: HbA1c < 6.5% vs. < 7%? | |
|
|
Sang Yong Kim(Chosun University, Korea) Bo Yeon Kim (Sooncheonhyang University, Korea) Eun-Jung Rhee(Sungkyunkwan University, Korea) |
|
| Diabetes drug, approval, insurance : Solutions to differences in diabetes drug aproval and insurance standards |
09:00~11:00 / Saturday 13 October Flamingo Chairman: Tae Sun Park, Seok O Park |
Overview |
|---|---|---|
Organizer: Committee of the health insurance and legislation session Diabetes drugs, which have annual sales of KRW 1 trillion, are different in their efficacy and indications. However, the range of coverage varies even for each series and each individual component, so the conflicts and burdens of prescribing physicians and patients are continuing. Based on the evidence and guidelines, we will discuss how to apply the principles of insurance standard setting to the development of effectiveness and safety verification and policy considerations for diabetics in Korea. |
||
|
RG5-1 Principles of setting up drug insurance standards, focusing on diabetes drugs | |
|
RG5-2 Proposal for the principle of insurance application of anti-diabetic drugs | |
|
|
RG5-Panel1 Gi Hyeon Seo(HIRA, Korea) RG5-Panel2 Kyeong Hye Park(National Health Insurance Ilsan Hospital, Korea) RG5-Panel3 Ministry of Food and Drug Safety |
|
